Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)

Booking.com

Oslo, Norway, 9 October 2019

Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators at Orano Med will present data and analyses from preclinical studies with 212Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the treatment of leukaemia and lymphoma at the 2019 Annual Congress of the European Association of Nuclear Medicine (12-16 October, Barcelona, Spain).

In the study, the efficacy of 212Pb-NNV003 was compared with ibrutinib in a disseminated mouse model using the ibrutinib-resistant cell line MEC-2. Ibrutinib is a Bruton’s tyrosine kinase (BTK)

Booking.com

Source: Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)

Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.